Online inquiry

IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14565MR)

This product GTTS-WQ14565MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), B cell acute lymphoblastic leukemia (B cell ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14565MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15817MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ4814MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ2364MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ3646MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ1204MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ7554MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ3081MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ1787MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-402
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW